Stock 6492 SENHWA BIOSCIENCES, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Senhwa Biosciences, Inc.

Equities

6492

TW0006492002

End-of-day quote Taipei Exchange
Other stock markets
 06:00:00 2024-04-29 pm EDT 		5-day change 1st Jan Change
41.45 TWD +0.36% Intraday chart for Senhwa Biosciences, Inc. +1.97% -18.57%
Mar. 20 Senhwa Biosciences Announces First Patient Dosed in the Phase II Study of Silmitasertib in Patients with Community-Acquired Pneumonia Associated with Viral Infection in Taiwan CI
Mar. 14 Senhwa Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Basal Cell Carcinoma Pipeline, FDA Approvals, Clinical Trials Developments and Companies 2023 (Updated)
AQ
Senhwa Biosciences Received US FDA IND Approval for Phase II Study of Silmitasertib in Patients with Community-Acquired Pneumonia Associated with Viral Infection
AQ
Senhwa Biosciences Announces First Patient Successfully Dosed in Taiwan Phase II Study of Silmitasertib in Hospitalized Adults with COVID-19
AQ
Medulloblastoma Pipeline: Emerging Therapies and Key pharma players involved by DelveInsight | Oncurious, Y-mAbs Therapeutics, Senhwa Biosciences, Sun Pharmaceutical, Roche and Others
AQ
Sh : Senhwa Biosciences Reports Positive Phase 1 Data of CX-5461 in Patients With Advanced Solid Tumors at 2019 SABCS
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. 6492 Stock
  4. News Senhwa Biosciences, Inc.
  5. Press Releases